carnitine has been researched along with Colitis, Ulcerative in 14 studies
Colitis, Ulcerative: Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| " PLC had a similar safety profile to placebo; the most common adverse events were gastrointestinal." | 2.76 | Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. ( Ardizzone, S; Bakulin, IG; Camerini, R; Ceracchi, M; D'Arienzo, A; Denapiene, G; Fociani, P; Gasbarrini, G; Grinevich, VB; Koch, M; Kupcinskas, L; Lesniakowski, K; Malecka-Panas, E; Mikhailova, TL; Poniewierka, E; Sishkova, E; Vago, G; Valpiani, D; Zerbi, P; Zhidkov, KP, 2011) |
| "Carnitine transport was very rapid and Na+ dependent (10s)." | 1.38 | Expression and functional analysis of intestinal organic cation/L-carnitine transporter (OCTN) in Crohn's disease. ( Bitton, A; Charlebois, P; Dionne, S; Elimrani, I; Girardin, M; Goyette, P; Levy, E; Qureshi, I; Rioux, J; Seidman, EG, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Li, P | 1 |
| Wang, Y | 1 |
| Luo, J | 1 |
| Zeng, Q | 1 |
| Wang, M | 1 |
| Bai, M | 1 |
| Zhou, H | 1 |
| Wang, J | 1 |
| Jiang, H | 1 |
| Talián, G | 2 |
| Lakner, L | 1 |
| Bene, J | 2 |
| Komlósi, K | 2 |
| Horváth, K | 2 |
| Gasztonyi, B | 2 |
| Miheller, P | 1 |
| Figler, M | 2 |
| Mózsik, G | 2 |
| Tulassay, Z | 1 |
| Melegh, B | 2 |
| Schicho, R | 1 |
| Nazyrova, A | 1 |
| Shaykhutdinov, R | 1 |
| Duggan, G | 1 |
| Vogel, HJ | 1 |
| Storr, M | 1 |
| De Preter, V | 1 |
| Geboes, KP | 1 |
| Bulteel, V | 1 |
| Vandermeulen, G | 1 |
| Suenaert, P | 1 |
| Rutgeerts, P | 1 |
| Verbeke, K | 1 |
| Mikhailova, TL | 1 |
| Sishkova, E | 1 |
| Poniewierka, E | 1 |
| Zhidkov, KP | 1 |
| Bakulin, IG | 1 |
| Kupcinskas, L | 1 |
| Lesniakowski, K | 1 |
| Grinevich, VB | 1 |
| Malecka-Panas, E | 1 |
| Ardizzone, S | 1 |
| D'Arienzo, A | 1 |
| Valpiani, D | 1 |
| Koch, M | 1 |
| Denapiene, G | 1 |
| Vago, G | 1 |
| Fociani, P | 1 |
| Zerbi, P | 1 |
| Ceracchi, M | 1 |
| Camerini, R | 1 |
| Gasbarrini, G | 2 |
| Turner, LV | 1 |
| Hamlin, PJ | 1 |
| Annunziata, ML | 1 |
| Hanauer, S | 1 |
| Girardin, M | 1 |
| Dionne, S | 1 |
| Goyette, P | 1 |
| Rioux, J | 1 |
| Bitton, A | 1 |
| Elimrani, I | 1 |
| Charlebois, P | 1 |
| Qureshi, I | 1 |
| Levy, E | 1 |
| Seidman, EG | 1 |
| Havasi, V | 1 |
| Hunyady, B | 1 |
| Kurutas, EB | 2 |
| Cetinkaya, A | 2 |
| Bulbuloglu, E | 2 |
| Kantarceken, B | 2 |
| Ciralik, H | 1 |
| Buyukbese, MA | 1 |
| Gumusalan, Y | 1 |
| Giancaterini, A | 1 |
| Mingrone, G | 1 |
| De Gaetano, A | 1 |
| Capristo, E | 1 |
| Calvani, M | 1 |
| Caso, V | 1 |
| Greco, AV | 1 |
| Johnson, JA | 1 |
| Böhmer, T | 1 |
| Rydning, A | 1 |
| Solberg, HE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II, Parallel-group, Placebo Controlled, Double-blind, Randomised, Multicenter Study to Investigate the Efficacy of Two Dosages of Propionyl-L-Carnitine Colon Release Tablets in Patients Affected by Ulcerative Colitis Under Oral Stable Treatment[NCT01026857] | Phase 2 | 121 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075] | Phase 1 | 42 participants | Interventional | 2003-09-30 | Completed | ||
| Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266] | Phase 2 | 94 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months
| Intervention | g (Mean) | |||||
|---|---|---|---|---|---|---|
| Lean Mass Baseline | Lean Mass 3 months | Lean Mass 6 months | Fat Mass Baseline | Fat Mass 3 months | Fat Mass 6 months | |
| SMA Type 1 | 4317.15 | 4993.92 | 5133.83 | 3011.37 | 3618.25 | 4316.08 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 2.28 | 2.32 |
| Cohort 1b Sitters Treatment | 2.93 | 2.37 |
| Cohort 2 Standers and Walkers - Treatment | 5.52 | 6.56 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 1.91 | 1.44 |
| Cohort 1b Sitters Treatment | 2.2 | 1.8 |
| Cohort 2 Standers and Walkers - Treatment | 5.3 | 5.85 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 5.46 | 5.28 |
| Cohort 1b Sitters Treatment | 5.45 | 5.26 |
| Cohort 2 Standers and Walkers - Treatment | 14.85 | 16.26 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 3.6 | 3.74 |
| Cohort 1b Sitters Treatment | 4.6 | 3.4 |
| Cohort 2 Standers and Walkers - Treatment | 13.65 | 16.85 |
Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Baseline visit (0 weeks) | 6 Month visit (V2) | Change from Baseline | |
| Cohort 1a Sitters Placebo Then Treatment | 20.0 | 20.6 | 0.6 |
| Cohort 1b Sitters Treatment | 16.6 | 16.8 | 0.2 |
"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)
| Intervention | Score (Mean) | |
|---|---|---|
| Modified Hammersmith Extend at S1 (-4 weeks) | Modified Hammersmith Extend at S2 (0 weeks) | |
| Cohort 2 Experimental | 47.0 | 48.3 |
2 trials available for carnitine and Colitis, Ulcerative
| Article | Year |
|---|---|
Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Carnitine; Cohort Studies; Col | 2011 |
Effects of propyonil-l-carnitine topical irrigation in distal ulcerative colitis: a preliminary report.
Topics: Administration, Topical; Adult; Carnitine; Colitis, Ulcerative; Enema; Humans; Male; Therapeutic Irr | 2001 |
12 other studies available for carnitine and Colitis, Ulcerative
| Article | Year |
|---|---|
Downregulation of OCTN2 by cytokines plays an important role in the progression of inflammatory bowel disease.
Topics: Adult; Animals; Anti-Inflammatory Agents; Carnitine; Cell Line; Colitis, Ulcerative; Crohn Disease; | 2020 |
Plasma carnitine ester profiles in Crohn's disease and ulcerative colitis patients with different IGR2230a_1 genotypes.
Topics: Adult; Carnitine; Case-Control Studies; Colitis, Ulcerative; Crohn Disease; Esters; Female; Genotype | 2009 |
Quantitative metabolomic profiling of serum and urine in DSS-induced ulcerative colitis of mice by (1)H NMR spectroscopy.
Topics: Animals; Carnitine; Colitis, Ulcerative; Creatine; Dextran Sulfate; Hypoxanthine; Ketone Bodies; Mag | 2010 |
Kinetics of butyrate metabolism in the normal colon and in ulcerative colitis: the effects of substrate concentration and carnitine on the β-oxidation pathway.
Topics: Adenosine Triphosphate; Adult; Biological Availability; Biopsy; Butyrates; Carnitine; Case-Control S | 2011 |
Is propionyl-L-carnitine therapy effective in ulcerative colitis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Carnitine; Colitis, Ulcerative; Female; Humans; Male | 2012 |
Can we treat ulcerative colitis with nutritional supplements?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Carnitine; Colitis, Ulcerative; Female; Humans; Male | 2012 |
Expression and functional analysis of intestinal organic cation/L-carnitine transporter (OCTN) in Crohn's disease.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Biological Transport; Carnitine; Child; Colitis, Ulce | 2012 |
Changes of plasma fasting carnitine ester profile in patients with ulcerative colitis.
Topics: Adolescent; Adult; Aged; Carnitine; Colitis, Ulcerative; Fasting; Fatty Acids; Female; Humans; Male; | 2006 |
Effects of antioxidant therapy on leukocyte myeloperoxidase and Cu/Zn-superoxide dismutase and plasma malondialdehyde levels in experimental colitis.
Topics: Acetylcysteine; Animals; Antioxidants; Carnitine; Colitis, Ulcerative; Free Radical Scavengers; Leuk | 2005 |
Effects of L-carnitine on oxidant/antioxidant status in acetic acid-induced colitis.
Topics: Acetic Acid; Animals; Carnitine; Colitis, Ulcerative; Disease Models, Animal; Inflammation Mediators | 2006 |
L-carnitine for treatment of distal ulcerative colitis.
Topics: Butyrates; Butyric Acid; Carnitine; Colitis, Ulcerative; Enema; Humans | 1992 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |